如何治疗淋巴系统恶性肿瘤患者的心血管并发症
本文以病例讨论为框架,阐述淋巴系统恶性肿瘤患者心血管毒性的管理。强调在癌症全程中保持警觉和准备,基线风险分层有助于指导治疗前、中、后的监测与早期干预,目标是在避免临床显著心血管事件的同时实现最佳肿瘤治疗。
要点
- 淋巴系统恶性肿瘤患者的心血管毒性显著影响发病率和死亡率。
- 心肌病、心力衰竭和心律失常是蒽环类药物、造血干细胞移植和放疗最受关注的问题。
- 基线风险分层有助于指导癌症治疗前、中、后的监测和早期干预。
核心结论
- 管理淋巴系统恶性肿瘤患者心血管并发症的关键在于癌症全程中的警觉和准备。
- 基线风险分层有助于指导治疗前、中、后的监测与早期干预,对获得最佳结局至关重要。
- 总体目标是在避免临床显著心血管事件并发症的同时,使淋巴系统恶性肿瘤患者获得最佳治疗。
研究设计与样本
- 本文为基于病例讨论的综述,未报告系统检索范围。
主要发现
- 新型疗法、与传统化疗联合及合理治疗序贯的明确使多种淋巴系统恶性肿瘤的预后得到改善。
- 因长期或多次序贯治疗干预而产生的毒性正变得越来越有影响。
- 淋巴系统恶性肿瘤患者的心血管毒性在发病率和死亡率方面意义重大。
- 整个心血管系统均可受累,但心肌病、心力衰竭和心律失常在使用蒽环类药物、造血干细胞移植和放疗的淋巴系统恶性肿瘤患者中仍是最大担忧。
临床怎么用
- 原文强调在癌症全程中保持警觉和准备,并以基线风险分层指导治疗前、中、后的监测与早期干预;原文未据此给出具体推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The prognosis of several lymphoid malignancies has improved through development of novel therapies, combination with traditional chemotherapies, and delineation of appropriate therapeutic sequencing. Toxicities that are arising because of prolonged or multiple sequential therapeutic interventions are becoming increasingly impactful. Among the broad spectrum of complications that patients with lymphoid malignancies may experience, cardiovascular toxicities are significant in terms of morbidity and mortality. The entire cardiovascular system can be affected, but cardiomyopathy, heart failure, and arrhythmias remain of greatest concerns with the use of anthracyclines, hematopoietic stem cell transplantation, and radiation therapy in patients with lymphoid malignancies. These aspects will be covered in this article within the framework of case-based discussions. Key to the management of cardiovascular complications in patients with lymphoid malignancies is awareness and preparedness across the cancer continuum. Baseline risk stratification helps to direct surveillance and early intervention efforts before, during, and after cancer therapy, which are paramount for the best possible outcomes. Along these lines, the overall goal is to enable the best possible therapies for lymphoid malignancies without the complications of clinically significant cardiovascular events.
引用
- Herrmann J, McCullough KB, Habermann TM, et al. How I treat cardiovascular complications in patients with lymphoid malignancies. Blood. 2022. PMID: 34752600. doi:10.1182/blood.2019003893
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。